/PRNewswire/ The cell therapy market is poised to grow by USD 21.061 billion from 2021 to 2026, progressing at a CAGR of 56.79% during the forecast period,.
/PRNewswire/ Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the.
Cellular Biomedicine Group Inc., a Rockville-based biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that the Food and Drug Administration (FDA) granted clearance of the Investigational New Drug (IND) application to proceed with the Phase 1b clinical development of its chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 .
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection accurately identified all patients who would eventually relapse, while other methods were less predictive, according to a study published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.